Zealand Pharma To Host Conference Call for Q2 2025 Results

Author: Evelyn Baker Updated: 08-07-2025 11:47 AM

Zealand Pharma's Upcoming Conference Call

Zealand Pharma A/S, a prominent biotechnology firm known for its innovative peptide-based medicines, has announced an important event on August 14, 2025. The company will hold a conference call at 2:00 PM CET, equivalent to 8:00 AM ET, to discuss its financial results for the second quarter of 2025.

Key Participants in the Call

The conference call will feature a lineup of executive members from Zealand Pharma. This includes Adam Steensberg, the President and Chief Executive Officer; Henriette Wennicke, the Chief Financial Officer; David Kendall, the Chief Medical Officer; and Eric Cox, the Chief Commercial Officer. Each participant brings a wealth of knowledge and expertise that will surely provide valuable insights into the company’s performance and growth strategies.

How to Participate in the Conference Call

For those interested in tuning into the call, a live audio webcast will be provided alongside a presentation that can be accessed through Zealand Pharma's investor relations section. It is advised to register for the call or the webcast at least 10 minutes before the commencement time for a seamless experience.

Accessing the Event Recording

After the call, a recording will be accessible on Zealand Pharma’s website, ensuring that anyone unable to join live can still catch up on the discussions and insights shared during the event.

About Zealand Pharma A/S

Founded in 1998, Zealand Pharma A/S has established itself as a leader in the biotechnology sector. With an impressive portfolio of over ten drug candidates in clinical development, the company has successfully brought two of these candidates to market, while three additional ones are in advanced stages of development. Zealand Pharma actively collaborates with various pharmaceutical companies, bolstering its commitment to developing high-quality peptide-based medicines.

Company's Growth and Future Outlook

Zealand Pharma's continuous innovation and strategic partnerships reflect its firm commitment to advancing medical science and providing effective treatment solutions. The company is not only focused on present outcomes but is also strategizing for a sustainable and productive future in the dynamic biotechnology landscape.

Company Contacts for Additional Information

For further inquiries regarding Zealand Pharma, interested parties can reach out to the following contacts:

Adam Lange (Investors)
Vice President, Investor Relations
Email: alange@zealandpharma.com

Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com

Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com

Frequently Asked Questions

What is the purpose of the Zealand Pharma conference call?

The call is intended to present the company's financial results for Q2 2025 and discuss future strategies.

Who will be speaking during the conference call?

The call will feature key executives including the CEO, CFO, CMO, and CCO.

How can I listen to the conference call?

Participants can join by accessing a live audio webcast available on Zealand Pharma’s website.

Will there be a recording of the call available?

Yes, a recording will be available on the company's website after the event concludes.

What is Zealand Pharma's main focus?

Zealand Pharma specializes in the discovery and development of innovative peptide-based medicines.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.